Clinical Trials of IBI3035 in Healthy Subjects

Evaluation of the Pharmacokinetics and Pharmacodynamics of IBI3035 and Awiqli? (Ecoporin Insulin Injection) in a Randomized, Open-label, Single-dose, Two-formulation, Crossover Design in Healthy Male Subjects in China: A Phase I Clinical Trial.

This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects

Study Overview

• Status: Not yet recruiting
• Conditions: Healthy Person
• Intervention / Treatment: Biological: IBI3035; Biological: Insulin icodec Injection

• Study Type: Interventional
• Enrollment (Estimated): 144
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Shanyu Xu; Phone Number: +86-0512-69566088; Email: shanyu.xu@innoventbio.com

Study Locations

• China
  • Chongqing Municipality
    • Chongqing, Chongqing Municipality, China, 402760
      • Bishan Hospital of Chongqing
      • Contact: Chengyong Tang; Phone Number: 18983286980; Email: 17235387@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria

The following inclusion criteria must be met:

1. Healthy male adult subjects aged 18 to 45 years (including 18 and 45 years, based on the date of signing the informed consent form) of Chinese nationality;
2. Body Mass Index (BMI) between 19.0 and 24.0 kg/m2 (including both values) at screening, and weight ≥ 50 kg;
3. Normal glucose tolerance at screening [3.9 mmol/L < fasting blood glucose < 6.1 mmol/L, and 2-hour post-glucose load blood glucose < 7.8 mmol/L in the oral glucose tolerance test (OGTT)]; normal insulin secretion function or abnormality without clinical significance as determined by the investigator [confirmed by the insulin release test (IRT)];
4. Glycated hemoglobin ≤ 6.0% at screening;
5. Agree to take effective contraceptive measures during the study period and within 6 months after the last dose and have no plan to donate sperm;
6. Able to understand the procedures and methods of this study, willing to strictly follow the clinical trial protocol to complete the trial, and voluntarily sign the informed consent form.

Exclusion Criteria

Subjects who meet any of the following exclusion criteria cannot be included in this study:

1. Known or suspected to be allergic to the investigational drug in this study;
2. Have taken any drugs that affect insulin hypoglycemic effects within 28 days before screening (such as corticosteroids, diuretics, epinephrine, salbutamol, glucagon, thyroid hormones, etc.);
3. Have a history of clinical significance as determined by the investigator at screening or before randomization, including diseases of the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, or any other disease that can significantly alter the absorption, metabolism, or elimination of drugs;
4. Have a clear diagnosis of hyperglycemia or hypoglycemia within 3 months before screening;
5. Have an increased risk of thrombosis at screening, including personal or family history of deep vein thrombosis;
6. Have abnormal indicators with clinical significance at screening or before randomization: vital signs, physical examination, laboratory tests, chest X-ray, and 12-lead ECG as determined by the investigator;
7. Have had a severe infection, trauma, or surgery within 4 weeks before screening;
8. Have smoked more than 5 cigarettes per day within 3 months before screening, or have smoked within 48 hours before using the investigational drug or cannot stop using any tobacco products during the trial;
9. Have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, or health supplements (except for regular vitamin supplements) within 2 weeks before screening;
10. Have donated blood ≥ 400 ml or had any component blood donation within 3 months before screening, or have lost a total of ≥ 400 ml of blood for any reason, or have a history of blood transfusion or use of blood products;
11. Have consumed more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 ml of beer, or 45 ml of spirits, or 150 ml of wine, and cannot abstain from alcohol within 48 hours before using the investigational drug;
12. Have consumed excessive amounts of tea, coffee, and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 ml) daily within 3 months before screening;
13. Have positive results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or Treponema pallidum antibodies;
14. Have a history of drug abuse or drug use within 3 months before screening, or have positive results for alcohol tests or urine drug screening at screening. 15. Participants who have participated in other clinical trials and used investigational drugs or medical devices within the 3 months prior to screening;

16. Participants with a weight change greater than 5% within the 3 months prior to screening [(maximum weight within the 3 months prior to screening - minimum weight within the 3 months prior to screening) / minimum weight within the 3 months prior to screening × 100%, as self-reported by the participant]; 17. Participants with any food allergies or special dietary requirements that prevent them from adhering to a uniform diet (such as intolerance to standard meal foods, lactose intolerance, etc.); 18. Participants who have experienced acute diseases during the screening period; 19. Participants with a history of fainting at the sight of needles or blood, who cannot tolerate venipuncture blood collection, or who have difficulty with blood collection; 20. Participants for whom the investigator deems there to be any circumstances that make them unsuitable for participation in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Insulin icodec Injection; The first cycle is Awiqli® 1 U/kg, and the second cycle is IBI3035 1 U/kg	Biological: IBI3035; IBI3035 administered subcutaneously(SC); Biological: Insulin icodec Injection; Insulin icodec Injection administered subcutaneously(SC)
Experimental: IBI3035; The first cycle is IBI3035 1 U/kg, and the second cycle is Awiqli® 1 U/kg	Biological: IBI3035; IBI3035 administered subcutaneously(SC); Biological: Insulin icodec Injection; Insulin icodec Injection administered subcutaneously(SC)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The area under the blood drug concentration-time curve from 0 to 168 hours	From 0 to 168 hours after administration
Area Under Curve Glucose Infusion Rate (AUCGIR) 0-168h	From 0 to 168 hours after administration

Secondary Outcome Measures

Outcome Measure	Time Frame
Area Under Curve (AUC0-84h)	From 0 to 84 hours after administration
Tmax	From 0 to 168 hours after administration
Glucose Infusion Rate (GIR) max	From 0 to 168 hours after administration
Area Under Curve Glucose Infusion Rate (AUCGIR) 24-48h	From 24 to 48 hours after administration
Adverse events (AE)	through study completion, an average of 16 weeks
The generation of Anti-drug antibodies (ADA) and Neutrolizing antibodies (NAb if required)	through study completion, an average of 16 weeks
Area Under Curve (AUC) 84-168h	From 84 to 168 hours after administration
Cmax	From 0 to 168 hours after administration
T1/2	From 0 to 168 hours after administration
tGIRmax	From 0 to 168 hours after administration
AUCGIR 144-168h	From 144 to 168 hours after administration
vital signs (Body temperature)	through study completion, an average of 16 weeks
laboratory tests (fasting plasma glucose (GLU))	through study completion, an average of 16 weeks
12-lead Electrocardiogram (RR interval, PR interval, heart rate (HR), QRS interval, QT interval, QTcF (QTcF = QT/RR^0.33))	through study completion, an average of 16 weeks
vital signs (pulse)	through study completion, an average of 16 weeks
vital signs (respiratory rate)	through study completion, an average of 16 weeks
vital signs (blood pressure: systolic, diastolic)	through study completion, an average of 16 weeks

Collaborators and Investigators

• Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): May 8, 2026
• Primary Completion (Estimated): July 30, 2027
• Study Completion (Estimated): August 31, 2027

Study Registration Dates

• First Submitted: April 21, 2026
• First Submitted That Met QC Criteria: May 11, 2026
• First Posted (Actual): May 15, 2026

Study Record Updates

• Last Update Posted (Actual): May 15, 2026
• Last Update Submitted That Met QC Criteria: May 11, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: insulin icodec
• Other Study ID Numbers: CIBI3035A101CN

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No